Myelodysplastic Syndromes

Diagnosis, Risk-Stratification, Management Updates in Myelodysplastic Syndromes

An overview of the diagnosis and management of MDS, including recent treatment, was discussed in a paper published in the American Journal of Hematology.

Myeloproliferative Neoplasms: How Do MPNs Affect Quality of Life?

By

Tom Greenhalgh

As myeloproliferative neoplasms (MPNs) are a rare form of blood cancer, patients may not be aware of its effects. How do MPNs affect a patient’s quality of life, and what do your patients need to know?

Possible Response Biomarkers Identified in Non-Del(5q) Lower-Risk Myelodysplastic Syndrome

By

Vicki Moore, PhD

Researchers seek to identify biomarkers that may be predictive of erythroid response in patients with lower-risk myelodysplastic syndromes without a chromosome 5q deletion.

Differences in Myelodysplastic Syndromes Treatment Guidelines Do Not Account for Variable Treatment Decisions

By

Jonathan Goodman, MPhil

Researchers sought to determine whether differences in treatment guidelines for MDS would account for nonadherence to expert guidance.

Leukemic Transformation in Patients With Myelodysplastic Syndrome With Myelofibrosis

By

Vicki Moore, PhD

Researchers sought to identify inflammation-related genes that may be associated with leukemic transformation in patients with MDS with myelofibrosis.

EU Approves Luspatercept for Select Patients With Myelodysplastic Syndrome or Beta-Thalassemia

By

Patricia Chaney

Researchers sought to review the EU’s marketing authorization for luspatercept to treat select patients with MDS or transfusion-dependent beta thalassemia.

IRF4 Gene Expression Associated With Development of Acute Myeloid Leukemia, Myelodysplastic Syndrome

By

Patricia Chaney

Researchers sought to determine whether IRF4 expression is associated with an increased susceptibility to de novo AML and myelodysplastic syndrome.

Disease Features in Young Patients With Myeloproliferative Neoplasms

By

Vicki Moore, PhD

Researchers found a high incidence of thromboembolic events in young patients with myeloproliferative neoplasms, especially polycythemia vera.

Lower Mutation Burden With Pevonedistat Plus Azacitidine Vs Azacitidine Alone in Patients With Myelodysplastic Syndromes

By

Vicki Moore, PhD

Researchers sought to determine whether pevonedistat plus azacitidine would result in a lower residual mutation load than seen with azacitidine alone in patients with MDS.

Study Shows Link Between Soluble CD40 Ligand and Tumor Necrosis Factor α in Patients With Myelodysplastic Syndrome

By

Vicki Moore, PhD

Researchers sought to determine whether there is a link between exposure to a soluble CD40 ligand (sCD40L) and expression of TNFα in bone marrow mononuclear cells from patients with MDS.

MRI, DECT Best for Detection of Iron Content in Patients With Myelodysplastic Syndrome

By

Vicki Moore, PhD

Researchers sought to determine what is the best method for detecting liver iron abundance in patients with MDS.

Plant-Derived Compound May Have Antitumor Activity in Myelodysplastic Syndromes

By

Vicki Moore, PhD

Researchers sought to determine whether an HSP90 inhibitor and a plant-derived coumarin would have antitumor effects in patients with MDS.

Epigenetic Analysis Outlines Factors Predicting HMA Response in MDS, AML

By

Jonathan Goodman, MPhil

Researchers sought to determine what factors may help predict what patients with MDS or AML would respond to treatment with azacitidine.

HFE Mutations Have Unknown Impact on Outcomes for Patients With Myelodysplastic Syndromes

By

Jonathan Goodman, MPhil

Researchers evaluated the rates and significance of HFE variants in a population of patients with MDS.

Paroxysmal Nocturnal Hemoglobinuria Clones Positive Predictor in Myelodysplastic Syndromes, Aplastic Anemia

By

Patricia Chaney

Researchers sought to determine whether paroxysmal nocturnal hemoglobinuria clones might predict treatment responses for patients with MDS and aplastic anemia.

Older Patients With MDS Have Survival Benefit From Transplantation

By

Patricia Chaney

Researchers assessed if older patients with high-risk myelodysplastic syndrome experience significant overall survival benefit from hematopoietic transplantation.

Analysis of the Prognostic Value of the Fibrinogen-Albumin Ratio Index

By

Vicki Moore, PhD

A new study evaluated the prognostic value of the Fibrinogen-Albumin Ratio Index in certain conditions.

Patients With CCUS and Morphologic Dysplasia May Be at Greater Risk for MDS Transition

By

Jonathan Goodman, MPhil

A team of researchers sought to determine whether morphologic dysplasia may serve as a biomarker of risk for transition to myelodysplastic syndrome in patients with clonal cytopenia of undetermined significance.

Mortality Risk With COVID-19 in Patients With Myeloproliferative Neoplasms

By

Vicki Moore, PhD

Observational, retrospective study revealed factors that may be linked to higher mortality risk in patients with MPN and COVID-19.

Combination Treatment With p53 Reactivator Yields High Clinical Response in TP53-Mutant Myelodysplastic Syndromes

By

Lauren Dembeck, PhD

A team of investigators sought to evaluate outcomes following combination treatment with eprenetapopt and azacitadine in TP53-mutant myelodysplastic syndromes, as well as in oligoblastic acute myeloid leukemia.

Durable Erythroid Response With Lenalidomide, Epoetin Alfa in Refractory Myelodysplastic Syndromes

By

Vicki Moore, PhD

A phase 3 trial suggests higher responses when epoetin alfa is added to lenalidomide in treatment of erythropoietin-refractory myelodysplastic syndromes.

PARP Inhibition Associated With Increased Risk for Secondary MDS, AML

By

Christina Bennett, MS

Investigators estimated the risk for myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) related to PARP inhibition.

Greater KIAA0125 Expression Is Poor Prognostic Factor for Myelodysplastic Syndrome

By

Patricia Chaney

Among patients with myelodysplastic syndrome, long noncoding RNA KIAA0125 may predict poorer overall survival and leukemia-free survival.

Immune Checkpoint Inhibitor Combination Therapy Promising for AML, MDS

By

Patricia Chaney

Researchers reviewed the challenges and future developments in ICI combination therapies for the treatment of patients with acute myeloid leukemia and myelodysplastic syndromes.

Simple Flow-Based Prognostic Score Developed for Patients With MDS

By

Susan Moench, PhD, PA-C

Although other flow cytometry–based prognostic scores have been proposed in the setting of MDS, their complexity has limited their clinical use.

Posttransplant Azacitidine for High-Risk Acute Myeloid Leukemia, Myelodysplastic Syndrome

By

Vicki Moore, PhD

There may be no relapse-free survival or overall survival benefits with posttransplant azaciditine in patients with high-risk AML or MDS.

Myelodysplastic Syndromes: Gene Expression Signatures May Predict Response to Azacitidine

By

Jonathan Goodman, MPhil

Among some patients with myelodysplastic syndrome, gene expression signatures appear to be predictive of response and primary resistance to azacitidine.

Adherence to Allogeneic Stem Cell Transplantation to Improve Survival in Myelodysplastic Syndromes

By

Jonathan Goodman, MPhil

With the exception of alloSCT and iron chelation therapy, many guideline treatments may not improve survival among patients with myelodysplastic syndrome.

Benefits of Hematopoietic Stem Cell Transplantation in Advanced Myelodysplastic Syndromes

By

Rita Aghjayan

Researchers studied survival in reduced-intensity conditioning HSCT vs non-HSCT approaches for older, transplantation-eligible patients with advanced MDS.

Imetelstat Shows Efficacy in Lower-Risk Myelodysplastic Syndrome

By

Andrea S. Blevins Primeau, PhD, MBA

The first-in-class imetelstat demonstrated clinically meaningful red blood cell transfusion independence rates in lower-risk MDS, according to results of a phase 2 trial.

Survival Benefit of GVHD in MDS Is Limited to Specific Patient Subgroup

By

Susan Moench, PhD, PA-C

A graft-vs-MDS effect of graft-vs-host disease has been observed for some patients with acute leukemia post-HSCT, but has been less well studied in those with MDS.

Prevalence of Iron Toxicity in Lower-Risk Myelodysplastic Syndromes

By

Jonathan Goodman, MPhil

Researchers aimed to determine iron and oxidative stress characteristics and their effects on survival in patients with lower-risk myelodysplastic syndrome.

Quercetin May Induce Autophagy in Myelodysplastic Bone Marrow, Mouse Model Suggests

By

Jonathan Goodman, MPhil

A study with murine models suggests that quercetin may induce autophagy in myelodysplastic bone marrow among patients with myelodysplastic syndrome.

Effects of 5-Azacitidine Dose Changes With Myelodysplastic Syndrome

By

Vicki Moore, PhD

For patients with myelodysplastic syndrome, 5-azacitidine treatment delays showed some links to outcomes, while dose reductions had less impact.

Personalized Prediction Model for Outcomes After Allogeneic HSCT for Myelodysplastic Syndromes

By

Lauren Dembeck, PhD

As transplantation-related complications are high among patients with MDS, determining which patients will benefit from HSCT is essential.

Premyelodysplastic Syndrome Blood Kinetics Linked to Survival, Disease Risk

By

Jonathan Goodman, MPhil

Premyelodysplastic syndrome blood kinetics are linked to both disease risk and overall survival.

Inqovi, an Oral Therapy for Myelodysplastic Syndromes, Gets FDA Approval

By

Brian Park, PharmD

The administration of cedazuridine with decitabine prevents the degradation of decitabine by CDA in the gastrointestinal tract and liver increasing its systemic exposure.

Novel Therapies Needed: Poor Prognosis of Patients With TP53-Mutated Myeloid Malignancies

By

Lauren Dembeck, PhD

Novel treatment options are needed to improve outcomes for patients with TP53-mutated myeloid neoplasms.

Prognostic Value of Immunomodulator in Higher-Risk Myelodysplastic Syndromes Treated With Azacitidine

By

Lauren Dembeck, PhD

Immunomodulator indoleamine-2,3-dioxygenase may be a promising predictor and therapeutic target for patients with higher-risk myelodysplastic syndromes.

SF3B1 Mutation in Clonal Cytopenia of Undetermined Significance Strongly Linked to Myelodysplastic Syndrome Development

By

Jonathan Goodman, MPhil

Given the prevalence, the IWG-PM evaluated available evidence to determine whether SF3B1-mutated MDS should be recognized as a distinct disease subtype.

Reduced Transfusion Burden With Luspatercept in Anemia From Lower-Risk Myelodysplastic Syndromes

By

Lauren Dembeck, PhD

Transfusion independence for at least 8 weeks was observed in 38% of patients receiving luspatercept compared with 13% of patients receiving placebo.

Age Does Not Affect Transplant Outcomes Among Patients With Myelodysplastic Syndrome

By

Jonathan Goodman, MPhil

Rates of nonrelapse mortality and 3-year overall survival were similar between patients 55 to 64 years old and patients 65 years or older who underwent transplantation.

Iron Chelation Therapy May Improve Overall Survival in Patients With Myelodysplastic Syndrome

By

Jonathan Goodman, MPhil

Researchers conducted a meta-analysis to determine whether iron chelation therapy leads to improved overall and leukemia-free survival in patients with myelodysplastic syndrome.

Factors Influencing Survival After Allogeneic Hematopoietic Stem Cell Transplantation in Myelodysplastic Syndrome

By

Lauren Dembeck, PhD

Transfusion dependence, very high-risk cytogenetics, and high serum ferritin were identified as risk factors for death in a multivariable analysis.

An Algorithm for Predicting Resistance to Hypomethylating Agents Using Genomic Biomarkers

By

Vicki Moore, PhD

Researchers identified 8 combinations of genes that could be used to predict whether a patient will respond to treatment with hypomethylating agents.

Outcomes Based on HSCT Conditioning Regimen for Patients With Myelodysplastic Syndromes

By

Vicki Moore, PhD

Nonmyeloablative conditioning was associated with increased nonrelapse mortality and shorter overall survival compared with reduced-intensity conditioning.

Novel Management Strategies for Myelodysplastic Syndromes

By

Caleb Rans, PharmD

Myelodysplastic syndromes display a high degree of heterogeneity, making it difficult to establish a standard of care for patients.

Androgen Therapy in Lower-Risk Myelodysplastic Syndrome Can Result in Hematologic Improvement

By

Megan Garlapow, PhD

Patients who received androgen therapy demonstrated improvements in erythroid, platelet, and neutrophil measures.

Prognostic Factors After Second Allogeneic HSCT in Patients With Relapsed Myelodysplastic Syndrome

By

Megan Garlapow, PhD

The rate of 5-year overall survival in patients with myelodysplastic syndrome who underwent second allogeneic hematopoietic stem cell transplantation was 25.3%.

Immunomodulatory Treatment Approaches for Myelodysplastic Syndromes

By

Roxanne Nelson, RN, BSN

A variety of immune pathways mediate the pathogenesis of myelodysplastic syndromes, suggesting that the immune system may be a feasible therapeutic target.

Intensive Chemotherapy May Be Beneficial for Younger Patients With Myelodysplastic Syndrome

By

Lauren Dembeck, PhD

Compared with hypomethylating agents, intensive chemotherapy was associated with higher overall response and complete remission rates.